Edwards Lifesciences Corp (EW) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edwards Lifesciences Corp (EW) has a cash flow conversion efficiency ratio of 0.061x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($651.90 Million) by net assets ($10.72 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see EW market cap overview for the company's overall valuation and market capitalisation.
Edwards Lifesciences Corp - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Edwards Lifesciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edwards Lifesciences Corp ranked by their cash flow conversion efficiency. Explore how high is Edwards Lifesciences Corp's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nebius Group N.V.
NASDAQ:NBIS
|
0.217x |
|
Roche Holding AG
SW:RO
|
0.195x |
|
Sandvik AB
ST:SAND
|
0.046x |
|
NATWEST GROUP SP.ADR/2
F:RYS
|
N/A |
|
Hindustan Unilever Limited
NSE:HINDUNILVR
|
0.128x |
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SHE:002384
|
0.020x |
|
Becton Dickinson and Company
NYSE:BDX
|
0.027x |
|
Nasdaq Inc
NASDAQ:NDAQ
|
0.051x |
Annual Cash Flow Conversion Efficiency for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual cash flow conversion efficiency of Edwards Lifesciences Corp from 1999 to 2025. View EW live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.34 Billion | $1.60 Billion | 0.154x | +186.34% |
| 2024-12-31 | $10.06 Billion | $542.30 Million | 0.054x | -59.58% |
| 2023-12-31 | $6.72 Billion | $895.80 Million | 0.133x | -36.45% |
| 2022-12-31 | $5.81 Billion | $1.22 Billion | 0.210x | -29.32% |
| 2021-12-31 | $5.84 Billion | $1.73 Billion | 0.297x | +28.77% |
| 2020-12-31 | $4.57 Billion | $1.05 Billion | 0.230x | -18.93% |
| 2019-12-31 | $4.15 Billion | $1.18 Billion | 0.284x | -3.66% |
| 2018-12-31 | $3.14 Billion | $926.80 Million | 0.295x | -11.68% |
| 2017-12-31 | $2.99 Billion | $1.00 Billion | 0.334x | +24.24% |
| 2016-12-31 | $2.62 Billion | $704.40 Million | 0.269x | +22.47% |
| 2015-12-31 | $2.50 Billion | $549.70 Million | 0.220x | -52.92% |
| 2014-12-31 | $2.19 Billion | $1.02 Billion | 0.467x | +53.88% |
| 2013-12-31 | $1.56 Billion | $472.70 Million | 0.303x | +19.98% |
| 2012-12-31 | $1.48 Billion | $373.80 Million | 0.253x | +7.49% |
| 2011-12-31 | $1.34 Billion | $314.50 Million | 0.235x | +22.32% |
| 2010-12-31 | $1.31 Billion | $251.40 Million | 0.192x | +34.61% |
| 2009-12-31 | $1.16 Billion | $165.30 Million | 0.143x | -18.11% |
| 2008-12-31 | $878.80 Million | $153.20 Million | 0.174x | -30.75% |
| 2007-12-31 | $835.00 Million | $210.20 Million | 0.252x | -18.26% |
| 2006-12-31 | $749.40 Million | $230.80 Million | 0.308x | +55.34% |
| 2005-12-31 | $690.00 Million | $136.80 Million | 0.198x | -31.05% |
| 2004-12-31 | $628.10 Million | $180.60 Million | 0.288x | +49.32% |
| 2003-12-31 | $635.10 Million | $122.30 Million | 0.193x | -13.87% |
| 2002-12-31 | $539.40 Million | $120.60 Million | 0.224x | +1.61% |
| 2001-12-31 | $459.00 Million | $101.00 Million | 0.220x | -29.33% |
| 2000-12-31 | $440.00 Million | $137.00 Million | 0.311x | +116.54% |
| 1999-12-31 | $1.22 Billion | $176.00 Million | 0.144x | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more